Monsoon miss cuts PAT 24.5%; margin gains mask volume collapse
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
—
confidence ?/10
Grade —
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
₹611.5 Cr
Revenue · −11.5% YoY₹43.9 Cr
Reported PAT · −24.5% YoYCompressing
Margins · vs guidance: OverstatedDid the claims hold up?
Delayed monsoon, not lost demand; recovery visible Q2 onwards
OVERSTATED13% volume decline, only 2% value growth in Q1; PAT fell 24.5% YoY despite 240bp gross margin expansion
Premium product mix driving profitability; 64% of B2C now
METPremium mix reached 64% (vs 58% prior year); but absolute PAT fell 24.5% — mix benefit masked by overall volume collapse
Cautious placement strategy to avoid high stock returns this year
METMD stated placements intentionally lower than last year; expects only 50% of prior year's ₹200 Cr returns
Granuvia and Spinoace will contribute ₹30–35 Cr gross in FY27
MISSGranuvia ~₹5 Cr in Q1, Spinoace ₹0.25 Cr (launch in late July); must ramp 6–7x to hit guidance
KAEROS scaling to second growth platform at 100% CAGR
Partial100 people hired, single-digit margins, expenses high; margin expansion uncertain
Guidance
No explicit FY27 total revenue target. Q1 miss acknowledged; recovery from Q2 expected but unquantified
LowMD deferred full-year guidance pending H1 review. Growth targets were 'aggressive' for 25th year; will revise after H1 close.
Granuvia & Spinoace: ₹30–35 Cr gross revenue in FY27 (₹25 Cr net)
MediumOnly ₹5.5 Cr in Q1; ramp dependent on farmer acceptance and distribution traction. Multi-year opportunity.
KAEROS: 100% CAGR initially, then 50–60%
MediumEarly stage; 100 people hired; single-digit margins. Margin expansion timeline unclear; expenses too high.
No explicit PAT or EBITDA margin target for FY27. Capex to normalize at ₹30–40 Cr post-Sotanala
LowCurrent quarter showed PAT margin 7.1% (down 130 bps); MD focused on ROCE improvement via working capital and utilization.
Focus on ROCE and ROE improvement post-Sotanala via operating leverage, efficiency, renewable energy
MediumQ3 onwards efficiency gains expected from solar, wind, solid fuel; reduced electricity and fuel costs.
Sotanala: ₹200 Cr total (₹50 Cr formulation, ₹150 Cr technical); ₹70 Cr invested to date; formulation by Apr–May 2027, technical by Diwali 2027
HighProject on schedule. Phased rollout: phase 1 complete by Diwali, phase 2 building erected, equipment decisions pending.
Post-Sotanala: annual capex normalize at ₹30–40 Cr maintenance capex (vs. current expansion phase)
MediumMarks end of major investment cycle. Future capex decisions deferred pending product mix clarity.
Risks the call surfaced
Monsoon & agricultural demand
HighDelayed monsoon in Q1 triggered 13% volume decline and 11.5% revenue fall. Rains improving but re-dependency remains. South India rice sowing 40% pending.
Raw material cost volatility
HighSolvents, plastics, emulsifiers, technicals prices highly volatile (25–30% week-to-week, some doubled). Supply chain disruption from China. Pricing power weak in soft demand.
Pricing power erosion
MediumAttempted 3 price hikes (March, April, May); had to roll back in May–July due to weak market sentiment and low demand. Only strategic hikes stuck. Commodity margins vulnerable (10–15%).
KAEROS profitability
MediumKAEROS hired 100 people in Q1; single-digit margins; expenses too high. Normalized margins still expected single-digit; timeline to profitability vague. Scale-up risk.
New product ramp (Granuvia, Spinoace)
MediumQ1 sales ₹5.5 Cr (Granuvia ~₹5, Spinoace ~₹0.25). FY27 target ₹30–35 Cr gross (₹25 Cr net) — requires 5–6x ramp in 3 quarters. Farmer adoption unproven; distribution capacity needed.
Capacity utilization at Dahej & Sotanala
MediumDahej at 50–60% utilization. Sotanala not yet commissioned (formulation by Apr–May 2027, technical by Diwali). ₹200 Cr investment dependent on product mix and demand recovery. Returns unquantified.
Management
Score 6/10. Realistic about Q1 weakness (monsoon, volume -13%, PAT -24.5%) but vague on recovery path. No explicit FY27 revenue or PAT targets given. Evasive on capacity ROI, KAEROS margin timeline, and some Q&A details. Candid on raw material volatility and pricing power constraints. Prior FY26 guidance for 'decent growth' in FY27 missed; Q1 -11.5% revenue and -24.5% PAT. MD acknowledged but deferred full-year targets to H1 review. Acknowledged monsoon was factor. Capex tracking (Sotanala ₹70 Cr of ₹200 Cr, on schedule). Premiumization on track (64% mix vs. 58% prior).
The call, decoded — read the verdict against the numbers.
Informational and educational content only. Not investment advice.